Dynavax directors favored over Deep Track slate

Dynavax Technologies is urging shareholders to re-elect its current board at the upcoming June 11, 2025 meeting, supported by recommendations from advisory firms Glass Lewis, ISS, and Egan Jones, who cite the board's strategic shift towards vaccine development and sector expertise; this comes amidst a proxy battle with Deep Track Capital, which is advocating for board changes. Despite a recent Q1 2025 EPS miss, Dynavax reported a 34% year-over-year revenue increase driven by HEPLISAV-B vaccine sales, maintaining its full-year revenue guidance and a 203% total return to stockholders over the past five years, while also completing over 85% of its $200 million share repurchase program.

Analysis

Dynavax Technologies (DVAX) is currently navigating a significant proxy contest initiated by shareholder Deep Track Capital ahead of its June 11, 2025, Annual Meeting, creating uncertainty around its board composition and strategic direction. While Dynavax asserts that advisory firms ISS and Egan Jones support its full slate of director nominees, and initially cited Glass Lewis's endorsement for all its nominees, a subsequent report within the article indicates Glass Lewis has actually recommended shareholders vote for two of Deep Track’s nominees, specifically highlighting concerns about Dynavax's capital allocation strategy. This governance challenge occurs despite the company's strong liquidity, evidenced by a current ratio of 11.93, and the market leadership of its HEPLISAV-B® vaccine, which achieved $268 million in 2024 net product revenue with a 44% U.S. market share and drove a 34% year-over-year revenue increase in Q1 2025. Dynavax maintains its full-year revenue guidance, expecting sales in the top half of its $305-$325 million range, and highlights a 203% total shareholder return over the past five years, alongside completing over 85% of its $200 million share repurchase program authorized in November 2024. However, the company reported a substantial Q1 2025 EPS miss at -$0.77, contrasting with a $0.04 forecast, and its stock trades near its 52-week low at $9.89. InvestingPro data suggests a Fair Value for the stock, with analyst price targets ranging from $11.10 to $31.00. The company’s future trajectory, particularly concerning its capital allocation and R&D initiatives for pandemic influenza and Lyme disease vaccines, hinges significantly on the outcome of the upcoming shareholder vote, reflecting the mixed sentiment signals (overall -0.15 score, DVAX specific -0.3) and high market impact (0.65 score) associated with these developments.

Key Decisions for Investors

• Investors should closely monitor the results of the June 11, 2025, Annual Meeting, as the outcome of the proxy contest with Deep Track Capital will be pivotal for Dynavax's board structure and strategic priorities, particularly concerning capital allocation.
• It is advisable to evaluate Dynavax's strong HEPLISAV-B market performance and revenue growth against the recent significant Q1 EPS miss, the ongoing governance dispute, and the stock trading near its 52-week low.
• Consider the potential long-term value from its vaccine pipeline and current share repurchase program, but weigh these against risks highlighted by Deep Track Capital and the reported concerns from Glass Lewis regarding the company's capital strategy.
• Re-assess investment positions based on the Annual Meeting's outcome and any subsequent clear articulations of the company's strategic direction or capital return policies by the elected board.